

barbiturate and non-benzodiazepine hypnotic compound  
and melatonin;

Group III: claim 46, drawn to a method of decreasing  
the dose of a non-barbiturate or non-benzodiazepine  
hypnotic compound through combination treatment with  
melatonin; and

Group IV: claim 47, drawn to a method of lessening the  
risk of the development of tolerance or dependence on a  
non-barbiturate or non-benzodiazepine hypnotic compound  
through combination treatment with melatonin.

Applicants hereby elect the claims of Group I, claims 29-37,  
for prosecution on the merits.

The examiner further has requested an election of species.  
Applicants hereby elect zolpidem (N,N,6-trimethyl-2-(4-

methylphenyl)-imidazo(1,2-a)pyridine-3-acetamide) as the non-barbiturate and non-benzodiazepine compound.

<input checked="" type="checkbox"/> Customer Number or Bar Code Label <b>6449</b>					
<i>Name</i>	Barbara G. Ernst, Reg. No. 30,377				
<i>Signature</i>	/ Barbara G. Ernst /			<i>Date</i>	March 26, 2009
<i>Address</i>	Rothwell, Figg, Ernst & Manbeck Suite 800, 1425 K Street, N.W.				
<i>City</i>	Washington	<i>State</i>	D.C.	<i>Zip Code</i>	20005
<i>Country</i>	U.S.A.	<i>Telephone</i>	202-783-6040	<i>Fax</i>	202-783-6031